Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 52, 2017, Pages 13792-13797

  Doherty, Mary R ^a   Cheon, HyeonJoo ^b   Junk, Damian J ^a   Vinayak, Shaveta ^a,c   Varadan, Vinay ^a   Telli, Melinda L ^d   Ford, James M ^d   Stark, George R ^a,b   Jackson, Mark W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Interferon beta; Triple negative breast cancer; Tumor microenvironment

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; MESSENGER RNA; STAT1 PROTEIN; STAT2 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; VIMENTIN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST EPITHELIUM CELL; CANCER STEM CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; BIOSYNTHESIS; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-BETA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85039755329     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1713728114     Document Type: Article

References (27)

1. Stagg J, Allard B (2013) Immunotherapeutic approaches in triple-negative breast cancer: Latest research and clinical prospects. Ther Adv Med Oncol 5:169-181.
2. Ling X, et al. (2010) Mesenchymal stem cells overexpressing IFN-β inhibit breast cancer growth and metastases through stat3 signaling in a syngeneic tumor model. Cancer Microenviron 3:83-95.
3. Lehmann B-D, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767.
4. Burstein M-D, et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-1698.
5. Nguyen D-X, Bos P-D, Massagué J (2009) Metastasis: From dissemination to organspecific colonization. Nat Rev Cancer 9:274-284.
6. Bidwell B-N, et al. (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18:1224-1231.
7. Doherty M-R, Smigiel J-M, Junk D-J, Jackson M-W (2016) Cancer stem cell plasticity drives therapeutic resistance. Cancers (Basel) 8:1-13.
8. Junk D-J, Cipriano R, Bryson B-L, Gilmore H-L, Jackson MW (2013) Tumor microenvironmental signaling elicits epithelial-mesenchymal plasticity through cooperation with transforming genetic events. Neoplasia 15:1100-1109.
9. Junk D-J, et al. (2017) Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 36:4001-4013.
10. Mani S-A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715.
11. Goldman A, et al. (2015) Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun 6:6139.
12. Liu S, et al. (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48.
13. Parker B-S, Rautela J, Hertzog P-J (2016) Antitumour actions of interferons: Implications for cancer therapy. Nat Rev Cancer 16:131-144.
14. Sistigu A, et al. (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20:1301-1309.
15. Yang X, et al. (2014) Targeting the tumor microenvironment with IFNβ bridges innate and adaptive immune responses. Cell 25:37-48.
16. Weichselbaum RR, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105:18490-18495.
17. Cheon H, Stark G-R (2009) Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 106:9373-9378.
18. Cheon H, et al. (2013) IFNβ-independent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 32:2751-2763.
19. Finak G, et al. (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8:R58.
20. Szasz A-M, et al. (2016) Cross-validation of survival associated data of 1,065 patients. Oncotarget 7:49322-49333.
21. Liu J-C, et al. (2012) Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα-breast cancer. Proc Natl Acad Sci USA 109:5832-5837.
22. Chen X, et al. (2012) TNBCtype: A subtyping tool for triple-negative breast cancer. Cancer Inform 11:147-156.
23. Telli M-L, et al. (2015) Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG0105. J Clin Oncol 33:1895-1901.
24. Qadir A-S, et al. (2017) CD95/Fas increases stemness in cancer cells by inducing a STAT1-dependent type I interferon response. Cell Rep 18:2373-2386.
25. Katlinski K-V, et al. (2017) Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31:194-207.
26. Migali C, et al. (2016) Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond. Ther Adv Med Oncol 8:360-374.
27. Parvani J-G, Gujrati MD, Mack MA, Schiemann WP, Lu ZR (2015) Silencing β3 integrin by targeted ECO/siRNA nanoparticle inhibits EMT and metastasis of triple negative breast cancer. Cancer Res 75:2316-2325.